Fifth Third Bancorp’s LENZ Therapeutics LENZ Stock Holding History

Fifth Third Bancorp’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-79	Closed	-$723	–	4463
2026 Q1	$723	Buy	+79	New	+$1.11K	﹤0.01%	4158

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Fifth Third Bancorp's LENZ Position: Q2 2026 in Review

Fifth Third Bancorp sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 79 shares — an estimated $723 sold.

Fifth Third Bancorp first reported a position in LENZ in Q1 2026 and held it in 1 quarter. The position peaked at $723 in Q1 2026. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Fifth Third Bancorp reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
Fifth Third Bancorp sold 79 LENZ Therapeutics shares in Q2 2026, an estimated $723.
Fifth Third Bancorp first reported a position in LENZ Therapeutics in Q1 2026 and held it in 1 quarter.
Fifth Third Bancorp's LENZ Therapeutics position peaked at $723 in Q1 2026.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.